Dashboard
Manage Tickers

CSLLYCSL LTD

OTC csl.com.au


$ 1.91 (2.14 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.96 $ 3.64 (0.84 %)
DIA $ 386.87 $ 0.13 (0.03 %)
SPY $ 511.25 $ 6.22 (1.23 %)
TLT $ 89.88 $ -0.23 (-0.26 %)
GLD $ 212.97 $ -0.45 (-0.21 %)
$ 91.05
-- x --
-- x --
-- - --
$ 71.06 - $ 103.66
23,917
na
0
$ 0.85
nm
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
ARS Pharmaceuticals Submits Response For n...
04/30/2024 13:23:04

CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issu...

fda-green-lights-pfizers-gene-therapy-for-rare-bleeding-disorder-hemophilia
FDA Green Lights Pfizer's Gene Therapy For...
04/26/2024 18:30:08

FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced...

Core News & Articles
Travere Therapeutics And CSL Vifor Announc...
02/23/2024 12:07:55

arcturus-therapeutics-lung-disease-candidate-triggers-bullish-rating-analyst-sees-over-200-upside
Arcturus Therapeutics' Lung Disease Candid...
12/13/2023 18:34:47

Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine...

credit-suisses-17b-of-at1-debt-written-down-to-zero-richard-bransons-virgin-orbit-plans-insolvency-court-freezes-volkswagens-russian-assets-todays-top-stories
Credit Suisse's $17B Of AT1 Debt Written D...
03/20/2023 14:00:13

Reuters

large-vaccine-players-including-gsk-moderna-prepare-for-bird-flu-vaccine-just-in-case
Large Vaccine Players Including GSK, Moder...
03/20/2023 11:54:00

travere-therapeutics-scores-accelerated-fda-approval-for-rare-kidney-disease-treatment
Travere Therapeutics Scores Accelerated FD...
02/21/2023 12:41:58

fda-approves-uniqures-hemgenix-first-hemophilia-b-gene-therapy-for-adults
FDA Approves UniQure's Hemgenix, First Hem...
11/23/2022 13:12:17

arcturus-shares-jump-after-collaboration-with-csl-for-mrna-based-vaccines
Arcturus Shares Jump After Collaboration W...
11/02/2022 11:43:43

travere-csls-sparsentan-application-is-under-european-review-for-rare-kidney-disorder
Travere, CSL's Sparsentan Application Is U...
08/22/2022 13:58:36

csl-posts-encouraging-data-from-garadacimab-in-severe-swelling-attacks
CSL Posts Encouraging Data From Garadacima...
08/17/2022 16:10:42

the-daily-biotech-pulse-fda-orphan-drug-tags-for-neurocrine-editas-candidates-sale-of-bridgebios-prv-rmat-designation-for-polaritytes-product
The Daily Biotech Pulse: FDA Orphan Drug T...
05/13/2022 14:38:25

Here's a roundup of top developments in the biotech space over the last 24 hours:

csl-seals-117b-buyout-deal-of-vifor-pharma-probably-the-largest-healthcare-deal-in-2021
CSL Seals $11.7B Buyout Deal Of Vifor Phar...
12/14/2021 19:36:34

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed&nb

Core News & Articles
COVID-19 Convalescent Plasma Study Shows N...
03/03/2021 10:20:49

The National Institutes of Health (NIH) has halted a trial evaluating the safety and effectiveness<

Core News & Articles
CSL Announced Commencement of Manufacturin...
11/08/2020 12:53:26

CSL (OTC: CSLLY) confirmed it will commence manufacturing the University of Oxford/AstraZeneca (NYSE: AZN) AZD1222 COVID-19 vac...

Core News & Articles
Stocks That Hit 52-Week Lows On Tuesday
03/24/2020 15:39:28

Core News & Articles
Stocks That Hit 52-Week Highs On Tuesday
03/24/2020 15:35:03

Core News & Articles
Stocks That Hit 52-Week Highs On Wednesday
02/19/2020 15:32:10

Core News & Articles
Stocks That Hit 52-Week Highs On Wednesday
02/12/2020 16:45:04

Core News & Articles
Stocks That Hit 52-Week Highs On Tuesday
02/11/2020 15:17:37

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION